標(biāo)題: Titlebook: Immunotherapy – A Novel Facet of Modern Therapeutics; Sujata P. Sawarkar,Vandana S. Nikam,Shariq Syed Book 2021 Springer Nature Singapore [打印本頁(yè)] 作者: 傷害 時(shí)間: 2025-3-21 16:58
書(shū)目名稱(chēng)Immunotherapy – A Novel Facet of Modern Therapeutics影響因子(影響力)
書(shū)目名稱(chēng)Immunotherapy – A Novel Facet of Modern Therapeutics影響因子(影響力)學(xué)科排名
書(shū)目名稱(chēng)Immunotherapy – A Novel Facet of Modern Therapeutics網(wǎng)絡(luò)公開(kāi)度
書(shū)目名稱(chēng)Immunotherapy – A Novel Facet of Modern Therapeutics網(wǎng)絡(luò)公開(kāi)度學(xué)科排名
書(shū)目名稱(chēng)Immunotherapy – A Novel Facet of Modern Therapeutics被引頻次
書(shū)目名稱(chēng)Immunotherapy – A Novel Facet of Modern Therapeutics被引頻次學(xué)科排名
書(shū)目名稱(chēng)Immunotherapy – A Novel Facet of Modern Therapeutics年度引用
書(shū)目名稱(chēng)Immunotherapy – A Novel Facet of Modern Therapeutics年度引用學(xué)科排名
書(shū)目名稱(chēng)Immunotherapy – A Novel Facet of Modern Therapeutics讀者反饋
書(shū)目名稱(chēng)Immunotherapy – A Novel Facet of Modern Therapeutics讀者反饋學(xué)科排名
作者: Anhydrous 時(shí)間: 2025-3-21 22:40
https://doi.org/10.1007/978-981-15-9038-2Immunotherapy; Cancer; Vaccine; Pharmacokinetics; Immunotherapeutics IPR; vaccines作者: 變態(tài) 時(shí)間: 2025-3-22 00:44 作者: 好色 時(shí)間: 2025-3-22 05:07
http://image.papertrans.cn/i/image/462314.jpg作者: legitimate 時(shí)間: 2025-3-22 09:29
Book 2021logy, neurodegenerative and autoimmune diseases, it discusses the drug delivery systems, and pre-clinical and clinical methodologies for immunotherapy-based drugs.? It also comprehensively reviews various aspects of immunotherapy, such as regulatory affairs, quality control, safety, and pharmacovigi作者: intrude 時(shí)間: 2025-3-22 15:27
Immunotherapy: A Concept,tic moieties based on immunotherapy have received regulatory approval and are being used in clinical practice. This chapter discusses a broad overview of the concept and principle of immunotherapy and its utility in a wide plethora of diseases.作者: 傀儡 時(shí)間: 2025-3-22 17:38 作者: bisphosphonate 時(shí)間: 2025-3-23 00:44
Future Immunotherapy Challenges and Perspectives,over, the avenues for the application of immunotherapy have also expanded. While originally aimed at the treatment of cancers, their potential applications have expanded to allergies, neurodegenerative diseases, infections, osteoporosis, and hyperlipidemia. The scope of immunotherapies moving forward will be discussed in this chapter.作者: 單挑 時(shí)間: 2025-3-23 03:28
ge coverage of the clinical biomarkers, drug delivery and scThis book illustrates the significance and relevance of immunotherapy in modern-day therapeutics. Focusing on the application of immunotherapy in oncology, neurodegenerative and autoimmune diseases, it discusses the drug delivery systems, a作者: 正論 時(shí)間: 2025-3-23 05:38
Book 2021 It also describes various design considerations and the scale-up synthesis of immunotherapeutics and screening methods. Lastly, it explores the important aspect of cost-effectiveness and rational immunotherapystrategies.?.作者: employor 時(shí)間: 2025-3-23 10:29
the function of a number of proteins encoded by candidate genes is still unknown. To date, over 20 genes have been shown to play a pivotal role in the origin of DCM. This diversity of genetic etiologies in DCM explains why patients sometimes exhibit additional clinical manifestations, including def作者: 得體 時(shí)間: 2025-3-23 14:07
Vritika Kulwal,Sujata Sawarkarcardiac defibrillator, while radiofrequency ablation has been recently reported as a potential new treatment. In 2016, a scoring system for diagnosis and risk stratification was proposed. This included electrocardiographic alterations, clinical findings, genetic basis, and family history.作者: Malfunction 時(shí)間: 2025-3-23 21:17
Shariq Syedndrial cardiomyopathy is suspected. Since mitochondria, and thus mutant mitochondrial DNA, are randomly distributed during the cell cycle, disease phenotype may vary greatly..Treatment for mitochondrial cardiomyopathies is mainly supportive and comprises a combination of diuretics, beta-blockers, an作者: 轉(zhuǎn)換 時(shí)間: 2025-3-24 02:15
Pratik Ogale,Vandana S. Nikam,Manish Gautam,Sunil Gairola,S. S. Jadhave most prevalent disease gene. The nonisolated forms of LVNC are caused by a range of rare genetic defects. Until now, in half of familial isolated LVNC, the genetic defect remains unknown. Genetic defects in a large number of sarcomere and other cardiomyopathy genes and in genes primarily associate作者: patriarch 時(shí)間: 2025-3-24 05:16 作者: Influx 時(shí)間: 2025-3-24 07:33 作者: Dri727 時(shí)間: 2025-3-24 11:23
Vandana S. Nikamergo periodic cardiac evaluation for the presence of LVH. In about half of all patients, a disease causing mutation can be detected in one of the genes encoding for sarcomeric proteins. Detection of a disease causing mutation allows predictive genetic testing in relatives, and facilitates identifica作者: MAG 時(shí)間: 2025-3-24 15:41
Krishna Baxi,Munira Momin,Sujata Sawarkarnormalities, ventricular arrhythmias with a LBBB morphology, functional and structural alterations of the RV, and fibro-fatty replacement in endomyocardial biopsy. Two-dimensional echocardiography, cineangiography and magnetic resonance are the imaging tools to visualize structural-functional abnorm作者: 提煉 時(shí)間: 2025-3-24 21:58 作者: 真實(shí)的你 時(shí)間: 2025-3-25 00:08
Preeti Kulkarni,Parsshava Mehta,Bharati Shriyan,Kalpita Gawit,Vikram Gota,Minal Ghante作者: electrolyte 時(shí)間: 2025-3-25 05:03 作者: Directed 時(shí)間: 2025-3-25 10:46 作者: promote 時(shí)間: 2025-3-25 12:23 作者: LAP 時(shí)間: 2025-3-25 17:31 作者: Gesture 時(shí)間: 2025-3-25 21:17 作者: DEI 時(shí)間: 2025-3-26 00:12 作者: 不給啤 時(shí)間: 2025-3-26 08:21
Companion Diagnostics and Clinical Biomarkers for Immunotherapy,ccess of oncology drugs like Herceptin and Imatinib, along with their companion diagnostic assays had accelerated the research in the?field. Even though oncology is the major segment for co-development of tests with corresponding targeted therapy, it is gradually expanding in other therapeutic areas作者: FISC 時(shí)間: 2025-3-26 10:29 作者: 責(zé)怪 時(shí)間: 2025-3-26 15:15 作者: convert 時(shí)間: 2025-3-26 18:18 作者: entitle 時(shí)間: 2025-3-26 21:09
Regulatory Affairs and Intellectual Property Rights in Immunotherapeutics,side effects than the drugs already available. These therapies also possess weak qualities to create any hostility during microbial disease treatment..This chapter provides in detail the regulator aspects of getting these drugs approved. The chapter aims to look at the various guidelines provided by作者: 倔強(qiáng)一點(diǎn) 時(shí)間: 2025-3-27 04:03 作者: MOCK 時(shí)間: 2025-3-27 05:36 作者: META 時(shí)間: 2025-3-27 10:46 作者: 充足 時(shí)間: 2025-3-27 14:07
Vritika Kulwal,Sujata Sawarkarly normal heart, leading to ventricular fibrillation and risk of sudden cardiac death. Currently, clinical diagnosis is based on a characteristic pattern in the electrocardiogram observed either spontaneously or induced during a pharmacological test. The prevalence varies among regions and ethniciti作者: perimenopause 時(shí)間: 2025-3-27 21:51
Shariq Syedpresent in the majority of patients with cardiomyopathy, arrhythmias, and conduction defects being the most prevalent. Hypertrophic cardiomyopathy is the most frequently encountered cardiomyopathy in PMD but also dilated cardiomyopathy and left ventricular non-compaction can occur. Cardiac symptoms 作者: facilitate 時(shí)間: 2025-3-27 23:05 作者: Tractable 時(shí)間: 2025-3-28 04:19 作者: 討好女人 時(shí)間: 2025-3-28 09:11 作者: Aqueous-Humor 時(shí)間: 2025-3-28 11:32
Vandana S. Nikams left ventricular hypertrophy (LVH) in the absence of abnormal loading conditions that may cause hypertrophy. The disease can present at any age and is highly variable in clinical expression. Patients can remain asymptomatic throughout their life, but HCM is also associated with premature mortality作者: cloture 時(shí)間: 2025-3-28 16:23 作者: Presbyopia 時(shí)間: 2025-3-28 19:21
Pratiksha Palahe,Vinal Pardhie, hypertension, valvular disease, and congenital heart disease sufficient to explain the observed myocardial abnormality. We describe five main cardiomyopathy subtypes as outlined by the European Society of Cardiology: hypertrophic cardiomyopathy, dilated cardiomyopathy, arrhythmogenic cardiomyopat作者: 圖表證明 時(shí)間: 2025-3-29 00:32 作者: Truculent 時(shí)間: 2025-3-29 05:30
Immunotherapy: A Concept,s. Immunotherapy is a type of treatment which involves induction, enhancement, or suppression of the immune system. This modern approach has changed the paradigm and revolutionized the concept of modern therapeutics. The approach lies on understanding the molecular basis of the disease and making me作者: prosthesis 時(shí)間: 2025-3-29 08:14 作者: Arable 時(shí)間: 2025-3-29 12:01
Vaccines as Immunotherapy,e responsible for causing cancer. Out of all known?cancers, almost 12% of them caused because of viruses. Seven viruses, namely Epstein–Barr virus (EBV), hepatitis B virus (HBV), human papillomavirus (HPV), human T-cell leukemia virus (HTLV), hepatitis C virus (HCV), Kaposi’s sarcoma-associated herp作者: coalition 時(shí)間: 2025-3-29 18:52 作者: Delude 時(shí)間: 2025-3-29 20:26 作者: 本能 時(shí)間: 2025-3-30 01:02
Companion Diagnostics and Clinical Biomarkers for Immunotherapy,atients respond differently to these drugs, which strongly suggests differential expression of biomarkers, albeit?with the same disease background. Thus, the concept of companion diagnostic-enable (CDx-enable) therapy evolved and?was clinically used to improve the benefits over risk. The non-respond作者: 欲望 時(shí)間: 2025-3-30 06:11 作者: 壟斷 時(shí)間: 2025-3-30 08:24 作者: 和平主義 時(shí)間: 2025-3-30 14:13
